Teva Pharmaceuticals has received U.S. regulatory approval for their Abbreviated New Drug Application (ANDA213191) on August 22, 2024, marking a significant milestone in their product_pipeline strategy and allowing for the introduction of this generic product to the market. This approval is expected to broaden the company's market share and drive incremental revenue growth as it fills this specific patient demand.